Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389932 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL3567880 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL11665011 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL3234142 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL11665013 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL15957077 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL2322263 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL20843407 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL18553838 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL185581 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2ATML3MBTL1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SMN1; SMN2 4787/4885ATM 1874/4885L3MBTL1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.